3-year progression-free survival rate 2 years follow-up after initiation of radiation therapy for the last patient enrolled [clinicaltrials_resource:69a48a2703bd7357ad6ffe0e0470ab16]
Evaluation will be in children and young adults with ependymoma treated with a second course of irradiation.
Outcomes will be reported by p-values.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
3-year progression-free survival rate 2 years follow-up after initiation of radiation therapy for the last patient enrolled [clinicaltrials_resource:69a48a2703bd7357ad6ffe0e0470ab16]
Evaluation will be in children and young adults with ependymoma treated with a second course of irradiation.
Outcomes will be reported by p-values.
Bio2RDF identifier
69a48a2703bd7357ad6ffe0e0470ab16
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:69a48a2703bd7357ad6ffe0e0470ab16
measure [clinicaltrials_vocabulary:measure]
3-year progression-free survival rate
time frame [clinicaltrials_vocabulary:time-frame]
2 years follow-up after initiation of radiation therapy for the last patient enrolled
description
Evaluation will be in children ...... will be reported by p-values.
identifier
clinicaltrials_resource:69a48a2703bd7357ad6ffe0e0470ab16
title
3-year progression-free surviv ...... for the last patient enrolled
@en
type
label
3-year progression-free surviv ...... 48a2703bd7357ad6ffe0e0470ab16]
@en